ALGS vs USB · rev $3.6M vs P/E 12, rev $28.66B
Aligos Therapeutics Inc (ALGS) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Aligos Therapeutics Inc (ALGS) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported ALGS revenue for 2024-12-31 was $3.6M. Net income was -$131.2M. Revenue was down 41.7% from 2023-12-31 to 2024-12-31. ALGS currently screens at market cap $44.1M.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
ALGS currently screens at market cap $44.1M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the ALGS and USB stock pages for the full models.
Not investment advice.